About Us
Alteron Therapeutics is a biopharmaceutical company dedicated to developing TDP-43 inhibitors for the treatment of neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), as well as cystic fibrosis (CF). We focus our goal-oriented and data-driven efforts on bringing out cures for these incurable diseases.